U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. About FDA
  3. FDA Organization
  4. Oncology Center of Excellence
  5. Oncology Regulatory Affairs and Policy Program
  1. Oncology Center of Excellence

Oncology Regulatory Affairs and Policy Program

Image
OCE Oncology Regulatory Affairs

The Oncology Regulatory Affairs and Policy Program in the Oncology Center of Excellence (OCE) collaborates with CDER, CBER, and CDRH to develop and execute an integrated regulatory approach to enhance the cross-center coordination of oncology product clinical review. The focus of Oncology Regulatory Affairs is the following:

  • Develop and implement procedures that affect the regulatory review of medical oncology products across centers.
  • Interact with colleagues in CDRH, CDER, and CBER to allow for a more coordinated review of products undergoing review by OCE.
  • Hold internal-facing meetings that allow for OCE policy development.
  • Provide a forum for oncology Regulatory Affairs to exchange ideas, streamline regulatory review processes and develop regulatory skills in resolving complex regulatory issues.
OCE Regulatory Projects
Back to Top